CSH guidelines for the diagnosis and treatment of drug-induced liver injury

Hepatology International

Volumn 11, Issue 3, 2017, Pages 221-241

  Yu, Yue cheng ^a   Mao, Yi min ^b   Chen, Cheng wei ^c   Chen, Jin jun ^d   Chen, Jun ^e   Cong, Wen ming ^f   Ding, Yang ^g   Duan, Zhong ping ^h   Fu, Qing chun ^c   Guo, Xiao yan ⁱ   Hu, Peng ^j   Hu, Xi qi ^k   Jia, Ji dong ^l   Lai, Rong tao ^b   Li, Dong liang ^m   Liu, Ying xia ⁿ   Lu, Lun gen ^b   Ma, Shi wu ^o   Ma, Xiong ^b   Nan, Yue min ^p   Ren, Hong ^j   Shen, Tao ^q   Wang, Hao ^r   Wang, Ji yao ^k   Wang, Tai ling ^s   Wang, Xiao jin ^c   Wei, Lai ^r   Xie, Qing ^b   Xie, Wen ^t   Yang, Chang qing ^u   Yang, Dong liang ^v   Yu, Yan yan ^w   Zeng, Min de ^b   Zhang, Li ^x   Zhao, Xin yan ^l   Zhuang, Hui ^q   more..

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c No 85 Hospital of PLA   (China)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

^e CENTRAL SOUTH UNIVERSITY   (China)

^f SECOND MILITARY MEDICAL UNIVERSITY   (China)

^g CHINA MEDICAL UNIVERSITY   (China)

^h CAPITAL MEDICAL UNIVERSITY   (China)

ⁱ XI'AN JIAOTONG UNIVERSITY   (China)

^j CHONGQING MEDICAL UNIVERSITY   (China)

^k FUDAN UNIVERSITY   (China)

^l CAPITAL MEDICAL UNIVERSITY   (China)

^m FUZHOU GENERAL HOSPITAL   (China)

ⁿ SHENZHEN THIRD PEOPLE S HOSPITAL   (China)

^o KUNMING GENERAL HOSPITAL   (China)

^p HEBEI MEDICAL UNIVERSITY   (China)

^q PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^r PEKING UNIVERSITY   (China)

^s CAPITAL MEDICAL UNIVERSITY   (China)

^t CAPITAL MEDICAL UNIVERSITY   (China)

^u TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^v HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^w PEKING UNIVERSITY FIRST HOSPITAL   (China)

^x BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

more..

Author keywords

Clinical type; Diagnosis; Differential diagnosis; Drug induced liver injury; Epidemiology; Pathogenesis; Pathology; Prevention; Recommendations; Treatment

Indexed keywords

ACETYLCYSTEINE; ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; BICYCLOL; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; GLUCOCORTICOID; GLYCYRRHIZIC ACID; HALOTHANE; HORMONES AND AGENTS ACTING ON THE ENDOCRINE SYSTEM; HOST FACTOR; LIVER PROTECTIVE AGENT; MAGNESIUM ISOGLYCYRRHIZINATE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; S ADENOSYLMETHIONINE; SILYMARIN; SPASMOLYTIC AGENT; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; ANTIINFECTIVE AGENT; HERBACEOUS AGENT;

ACUTE DISEASE; AGE; ALTERNATIVE MEDICINE; BENIGN INTESTINE TUMOR; BIOMEDICINE; CAUSALITY; CHINESE MEDICINE; CHRONIC DISEASE; CLASSIFICATION ALGORITHM; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DIETARY SUPPLEMENT; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; DRUG CONTAMINATION; DRUG PACKAGING; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EDITORIAL; ENVIRONMENTAL FACTOR; HEALTH PRODUCT; HEPATITIS; HEREDITY; HISTOPATHOLOGY; HUMAN; INCIDENCE; LABORATORY TEST; LIVER CELL DAMAGE; LIVER INJURY; LIVER TRANSPLANTATION; LIVER TUMOR; MALIGNANT NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATIENT EDUCATION; PATIENT MONITORING; PRACTICE GUIDELINE; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEX; TOXIC HEPATITIS; TREND STUDY; ULTRASOUND; ADVERSE EFFECTS; CHEMICALLY INDUCED; CHINA; CHOLESTASIS; COMPLICATION; FEMALE; LIVER DISEASE; MALE; PATHOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; TOXICITY;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHINA; CHOLESTASIS; DIAGNOSIS, DIFFERENTIAL; DIETARY SUPPLEMENTS; DRUGS, CHINESE HERBAL; FEMALE; GUIDELINES AS TOPIC; HUMANS; INCIDENCE; LIVER DISEASES; MALE; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 85028282488     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-017-9793-2     Document Type: Editorial

References (148)

1. Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–1425
2. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32(1):55–68
3. Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guide: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–966
4. Devarbhavi H. An update on drug—induced liver injury. J Clin Exp Hepatol. 2012;2(3):247–259
5. Hillman L, Gottfried M, Whitsett M, et al. Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury. Am J Gastroenterol. 2016;111(7):958–965
6. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924–1934
7. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52(6):2065–2076
8. Miguel A, Azevedo LF, Araújo M, Pereira AC. Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2012;21(11):1139–1154
9. Li L, Jiang W, Wang JY. Clinical analysis of 275 cases of acute drug-induced liver disease. Front Med China. 2007;1(1):58–61
10. Hoofnagle JH, Serrano J, Knoben JE, et al. LiverTox: a website on drug-induced liver injury. Hepatology. 2013;57(3):873–874
11. Yimin M. HepaTox: The professional networking platform for promoting clinical and translational research of drug-induced liver injury in China. Chin Hepatol 2014;(8):575–576 (article in Chinese)
12. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22(2):145–155
13. Bjornsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014;34(2):115–122
14. Lai RT, Wang H, Gui HL, et al. Clinical and pathological features in 138 cases of drug-induced liver injury. Chin J Hepatol 2012;20(3):185–189 (article in Chinese)
15. Hao KY, Yu YC, He CL, et al. Analysis on the diagnosis, clinical features and prognosis of 140 cases with drug-induced liver injury based on the RUCAM scales. Chin J Hepatol 2014;22(12):82–85 (article in Chinese)
16. Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10(8):1018–1023
17. Bjornsson E, Jerlstad P, Bergqvist A, et al. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand J Gastroenterol. 2005;40(9):1095–1101
18. Hou FQ, Zeng Z, Wang GQ. Hospital admissions for drug-induced liver injury: clinical features, therapy, and outcomes. Cell Biochem Biophys. 2012;64(2):77–83
19. Stine JG, Lewis JH. Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol. 2011;7(7):875–890
20. Hoofnagle JH, Navarro VJ. Drug-induced liver injury: Icelandic lessons. Gastroenterology. 2013;144(7):1335–1336
21. Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology. 2009;49(6):2001–2009
22. Elinav E, Pinsker G, Safadi R, et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J Hepatol. 2007;47(4):514–520
23. Azizi F, Amouzegar A. Management of hyperthyroidism during pregnancy and lactation. Eur J Endocrinol. 2011;164:871–876
24. Martinez MA, Vuppalanchi R, Fontana RJ, et al. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol. 2015;13(2):369–376
25. Saadi T, Waterman M, Yassin H, et al. Metformin-induced mixed hepatocellular and cholestatic hepatic injury: case report and literature review. Int J Gen Med. 2013;6:703–706
26. Soriano V, Puoti M, Garcia-Gasco P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22(1):1–13
27. Pais R, Rusu E, Ratziu V. The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease. Clin Liver Dis. 2014;18(1):165–178
28. Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology. 2006;44(6):1581–1588
29. Sharma SK1, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166(7):916–919
30. Pukenyte E, Lescure FX, Rey D, et al. Incidence of and risk factors for severe liver toxicity in HIV-infected patients on anti-tuberculosis treatment. Int J Tuberc Lung Dis 2007;11(1):78–84
31. Mitchell JR, Long MW, Thorgeirsson UP, et al. Acetylation rates and monthly liverfunction tests during one year of isoniazid preventive therapy. Chest. 1975;68(2):181–190
32. Shayiq RM, Roberts DW, Rothstein K, et al. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: an explanation for high acetaminophen dosage in humans without hepatic injury. Hepatology. 1999;29(2):451–463
33. Watkins PB, Zimmerman HJ, Knapp MJ, et al. Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease. JAMA. 1994;271(13):992–998
34. Zamor PJ, Russo MW. Liver function tests and statins. Curr Opin Cardiol. 2011;26:338–341
35. Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology. 2011;53(4):1377–1387
36. Khandelwal N, James LP, Sanders C, et al. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology. 2011;53(2):567–576
37. Guengerich FP. Cytochrome P450 Activation of Toxins and Hepatotoxicity. In Kaplowitz N, DeLeve LD. Drug Induced Liver Disease, 3rd ed. New York: Elsevier; 2013. 15–33
38. Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev. 2012;44(1):116–126
39. Russmann S, Jetter A, Kullak-Ublick GA. Pharmacogenetics of drug-induced liver injury. Hepatology. 2010;52(2):748–761
40. Wei CY, Lee MTM, Chen YT. Pharmacogenomics of adverse drug reactions: implementing personalized medicine. Hum Mol Genet. 2012;21(R1):R58–R65
41. Alfirevic A, Gonzalez-Galarza F, Bell C, et al. In silico analysis of HLA associations with drug-induced liver injury use of a HLA-genotyped DNA archive from healthy volunteers. Genome Med. 2012;4(6):51
42. Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenom J. 2008;8(3):186–195
43. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nature. 2010;42(8):711–714
44. Pessayre D, Fromenty B, Berson A, et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev. 2012;44(1):34–87
45. 2 during mitochondrial proline oxidation. Redox Biol. 2014;2:901–909
46. Finkel T. Signal transduction by reactive oxygen species. J Cell Biol. 2011;194:7–15
47. Choumar A, Tarhuni A, Letteron P, et al. Lipopolysaccharide-induced mitochondrial DNA depletion. Antioxid Redox Signal. 2011;15:2837–2854
48. Kim JS, He L, Qian T, et al. Role of the mitochondrial permeability transition in apoptotic and necrotic death after ischemia/reperfusion injury to hepatocytes. Curr Mol Med. 2003;3(6):527–535
49. Nakagawa H, Maeda S, Hikiba Y, et al. Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology. 2008;135:1311–1321
50. Jaeschke H, McGill MR, Williams CD, et al. Current issues with acetaminophen hepatotoxicity—a clinically relevant model to test the efficacy of natural products. Life Sci. 2011;88(17–18):737–745
51. Martin-Murphy BV, Holt MP, Ju C. The role of damage associated molecular pattern molecules in acetaminophen induced liver injury in mice. Toxicol Lett 2010;192(3):387–394
52. Janssens S, Pulendran B, Lambrecht BN. Emerging functions of the unfolded protein response in immunity. Nat Immunol. 2014;15(10):910–919
53. Dara L, Ji C, Neil Kaplowitz N. The contribution of endoplasmic reticulum stress to liver diseases. Hepatology. 2011;55(5):1752–1763
54. Fredriksson L, Wink S, Herpers B, et al. Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFα-mediated hepatotoxicity. Toxicol Sci. 2014;140(1):144–159
55. Lai R, Xiang X, Mo R, et al. Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury. J Hepatol. 2015;63(1):148–155
56. Masson MJ, Collins LA, Pohl LR. The role of cytokines in the mechanism of adverse drug reactions. Handb Exp Pharmacol. 2010;196:195–231
57. Uetrecht J. Immunoallergic drug-induced liver injury in humans. Semin Liver Dis. 2009;29(4):383–392
58. Vandenabeele P, Galluzzi L, Vanden Berghe T, et al. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol. 2010;11(10):700–714
59. Ke PY, Chen SS. Hepatitis C virus and cellular stress response: implications to molecular pathogenesis of liver diseases. Viruses 2012;4(10):2251–2290
60. Henkel A, Green RM. The unfolded protein response in fatty liver disease. Semin Liver Dis. 2013;33(4):321–329
61. Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146(4):914–928
62. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an update on the 2007 overview. Expert Opin Drug Saf. 2014;13(1):67–81
63. Ju C, Reilly T. Role of immune reactions in drug-induced liver injury (DILI). Drug Metab Rev. 2012;44(1):107–115
64. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56(4):958–976
65. Chalasani N, Björnsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology. 2010;138(7):2246–2259
66. Eisenberg-Lerner A, Kimchi A. PKD is a kinase of Vsp34 that mediates ROS-induced autophagy downstream of DAPk. Cell Death Differ 2012;19:788–797
67. Ding WX, Manley S, Ni HM. The emerging role of autophagy in alcoholic liver disease. Exp Biol Med. 2011;236:546–556
68. Roth RA, Ganey PE. Role of inflammation in drug-induced liver injury. In: Kaplowitz N, Deleve LD, editors. Drug-Induced Liver Disease. 3rd ed. San Diego: Academic Press; 2013. 157–173
69. Wu MH, Zang P, Huang X. Toll-like receptors in innate immunity and infectious diseases. Front Med China. 2010;4(4):385–393
70. Hansen JD, Vojtech LN, Laing KJ. Sensing disease and danger: a survey of vertebrate PRRs and their origins. Dev Comp Immunol. 2011;35(9):886–897
71. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005;4(6):489–499
72. Mehendale HM. Tissue repair: an important determinant of final outcome of toxicant-induced injury. Toxicol Pathol. 2005;33(1):41–51
73. Kleiner DE. Histopathological Evaluation of Drug-Induced Liver Disease. In Kaplowttz N, DeLeve LD, ed. Drug-induced Liver Disease, 3rd ed. New York, Academic Press; 2013. 241–261
74. Goodman ZD. Drug hepatotosicity. Clin Liver Dis. 2002;6(2):381–397
75. Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol. 2009;62(6):481–492
76. Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis. 2009;29(4):364–372
77. Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol. 2008;22(4):335–353
78. Tang W. Drug metabolite profiling and elucidation of drug induced hepatotoxicity. Expert Opin Drug Metab Toxicol. 2007;3(3):407–420
79. Hayashi PH, Fontana RJ. Clinical features, diagnosis, and natural history of drug-induced liver injury. Semin Liver Dis. 2014;34(2):134–144
80. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129(2):512–521
81. Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52(2):730–742
82. Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology. 2014;147(1):96–108
83. Borraz, Y, Fernandez MC, Garcia-Muhoz B, et al. Would it be desirable to modify the cut-off point for definition of chronicity in drug-induced liver injury (DILI)? In 61st Annual Meeting of the American Association for the Study of Liver Diseases; 2010. A270
84. Robles-Diaz M, Lucena MI, Kaplowitz N, et al; Spanish DILI Registry; SLatinDILI Network; Safer and Faster Evidence-Based Translation Consortium. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014;147(1):109–118
85. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014;89(1):95–106
86. Gao H, Li N, Wang JY, et al. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. J Dig Dis. 2012;13(1):33–39
87. Fan CQ, Crawford JM. Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol. 2014;4(4):332–346
88. Kootte AM, Siegel AM, Koorenhof M. Generalised peliosis hepatis mimicking metastases after long-term use of oral contraceptives. Neth J Med. 2015;73(1):41–43
89. Yu CY, Chang LC, Chen LW, et al. Peliosis hepatis complicated by portal hypertension following renal transplantation. World J Gastroenterol. 2014;20(9):2420–2425
90. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123(4):1367–1384
91. Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf 2011;(3)34:243–252
92. Eguchi A, Wree A, Feldstein AE. Biomarkers of liver cell death. J Hepatol. 2014;60(5):1063–1074
93. Watkins PB, Seligman PJ, Pears JS, et al. Using controlled clinical trials to learn more about acute drug-induced liver injury. Hepatology. 2008;48(5):1680–1689
94. Fannin RD, Russo M, O’Connell TM, et al. Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. Hepatology. 2010;51(1):227–236
95. Su YW, Chen X, Jiang ZZ, et al. A panel of serum microRNAs as specific biomarkers for diagnosis of compound- and herb-induced liver injury in rats. PLoS One. 2012;7(5):e37395
96. Bala S, Petrasek J, Mundkur S, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology. 2012;56(5):1946–1957
97. Antoine DJ, Dear JW, Lewis PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology. 2013;58(2):777–787
98. Watkins PB. Biomarkers for drug-induced liver injury. In: Kaplowitz N, Deleve LD, editors. Drug-Induced Liver Disease. 3rd ed. San Diego: Academic Press; 2013. 275–286.
99. Kenna JG. Current concepts in drug-induced bile salt export pump (BSEP) interference. Curr Protoc Toxicol 2014;61:23.7.1–23.7.15
100. Stephens C, Andrade RJ, Lucena MI. Mechanisms of drug-induced liver injury. Curr Opin Allergy Clin Immunol. 2014;4(4):286–292
101. Lin G, Wang JY, Li N, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol. 2011;54(4):666–673
102. Vuppalanchi R, iangpunsakul S, Chalsani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States. Am J Gastroenterol 2007;102(3):558–562
103. Loras C, Gisber JP, Minguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010;59(10):1340–1346
104. Makar GA, Weiner MG, Kimmel SE, et al. Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population. Pharmacoepidemiol Drug Saf. 2008;17(1):43–51
105. Aithal GP, Watkins PB, Andrade RJ. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–815
106. Danan G, Benichou C. Causality assessment of adverse reactions to drugs I. A novel method based on the conclusions of international consensus meetings: application to drug induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–1330
107. http://livertox.nlm.nih.gov/rucam.html. Accessed 28 Mar 2017
108. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17(1):14–46
109. Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug induced hepatitis. Hepatology. 1997;26(3):664–669
110. Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33(1):123–130
111. García-Cortés M, Lucena MI, Pachkoria K, et al. Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 2008;27(9):780–789
112. [InlineMediaObject not available: see fulltext.][InlineMediaObject not available: see fulltext.]. 2005;46(2):85–90 (articles in Japanese).
113. Hepatobiliary Diseases Cooperation Group of CSG. Recommendations for the diagnosis and treatment of acute drug-induced liver injury (draft). Chin J Dig 2007;27(11):765–767 (articles in Chinese).
114. Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel–Uclaf causality assessment method. Hepatology. 2010;51(6):2117–2126
115. Research Group of Liver Failure and Artificial Liver; Society of Infectious Disease (SID); Chinese Medical Association (CMA); Research Group of Severe Liver Disease and Artificial Liver; Chinese Society of Hepatology (CSH); CMA. Guidelines for diagnosis and treatment of liver failure (2012 edition). Chin J Hepatol 2013;21(3):178–179 (articles in Chinese).
116. Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the study of liver diseases position paper on acute liver failure 2011. Hepatology. 2012;55(3):965–967
117. http://livertox.nlm.nih.gov/Severity.html. Accessed 28 Mar 2017
118. Palmore TN, Shah NL, Loomba R, et al. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol. 2009;7(10):1130–1137
119. Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54(3):931–939
120. Miao Q, Bian Z, Tang R, et al. Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis. Clin Rev Allergy Immunol. 2015;48(2–3):226–235
121. Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51(6):2040–2048
122. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731–739
123. Wu S, Xia Y, Lv X, et al. Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a largecohort of Chinese patients. J Gastroenterol Hepatol. 2015;30(3):540–545
124. Ford R, Schwartz L, Dancey J, US Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER), et al. Guidance for industry: drug-induced liver injury—premarketing clinical evaluation. Eur J Cancer. 2009;45(2):268–274
125. Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008;359(3):285–292
126. Masubuchi Y, Nakayama J, Sadakata Y. Protective effects of exogenous glutathione and related thiol compounds against drug-induced liver injury. Biol Pharm Bull. 2011;34(3):366–370
127. Berk M, Malhi GS, Gray LJ, et al. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013;34(3):167–177
128. Zwingmann C, Bilodeau M. Metabolic insights into the hepatoprotective role of N-acetylcysteine in mouse liver. Hepatology. 2006;43(3):454–463
129. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137(3):856–864
130. Bateman DN, Dear JW, Thanacoody HK, et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomized controlled trial. Lancet. 2014;383(9918):697–704
131. Singh S, Hynan LS, Lee WM, Acute Liver Failure Study Group. Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci. 2013;58(5):1397–1402
132. Mao YM, Zeng MD, Chen Y, et al. Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: a randomized, double-blind, multi-doses, active drug controlled, multi-center study. Chin J Hepatol 2009;17(11):847–851 (article in Chinese)
133. Li X, Zhou J, Chen S, et al. Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer. J Int Med Res. 2014;42(4):906–914
134. Chu NH, Li L, Zhang X, et al. Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease. Int J Tuberc Lung Dis. 2015;19(4):475–480
135. Zhang QH, Shi GF, Li Q. Effects of diammonium glycyrrhizinate enteric-coated capsule in the treatment of 2396 cases with chronic hepatitis. Chin J Infect Dis 2007;25(3):175–176 (article in Chinese)
136. Abenavoli L, Capasso R, Milic N, et al. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010;24(10):1423–1432
137. Nathwani RA, Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis. 2006;10(2):207–217
138. Ni LD, Xie Q, Li HW, et al. Ursodeoxycholic acid in the treatment of drug-injury: an open controlled clinical trial. Chin Hepatol 2009;14(4):278–280 (article in Chinese)
139. Zhao P, Duan GF, Du L, et al. Systematic evaluation on the efficacy of ademetionine in patients of drug-induced liver injury. Chin J Gastroenterol Hepatol 2011;20(4):341–344 (article in Chinese)
140. Mato JM, Lu SC. Role of S-adenosyl-l-methionine in liver health and injury. Hepatology. 2007;45(5):1306–1312
141. Vincenzi B, Santini D, Frezza AM, et al. The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen. Expert Opin Drug Saf. 2011;10(3):345–349
142. Jeong R, Lee YS, Sohn C, et al. Model for end-stage liver disease score as a predictor of short-term outcome in patients with drug-induced liver injury. Scand J Gastroenterol. 2015;50(4):439–446
143. Yu YC, Chen CW. Interpretation of ACG clinical guidelines for the diagnosis and treatment of idiosyncratic drug-induced liver injury. Chin Hepatol 2014;19(8):570–574 (article in Chinese)
144. Zhang L, Yang XH. Phamacovigilance concept should be introduced sufficiently into the process of safety monitoring and evaluation of Chinese traditional medicine. Chin J Integr Tradit Western Med 2009;29(9):863–866 (article in Chinese)
145. Zhang L, Wong LY, He Y, Wong IC. Pharmacovigilance in China: current situation, successes and challenges. Drug Saf. 2014;37(10):765–770
146. Graham DJ, Mosholder AD, Gelperin K, et al. Pharmacoepidemiology and risk management. In: Strom BL, editor. Pharmacoepidemiology. 4th ed. West Sussex: Wiley; 2005. 51530.
147. Olson S, Robinson S, Giffin R; Institute of Medicine. Accelerating the development of biomarkers for drug safety: workshop summary. National Academies Press. Watkins PB, Bloom J, Hunt C. Biomarkers of Acute Idiosyncratic Hepatocellular Injury in Clinical Trials, Chap 5. 2009. 4257
148. Willy M, Li Z. What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA-approved product labeling. Pharmacoepidemiol Drug Saf. 2004;13(4):201–206